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Cancer is the second leading cause of death in the United States with 1.7 million
new cases estimated to be diagnosed in 2016. This disease remains a formidable
clinical challenge and represents a substantial financial burden to the US health care
system. Therefore, research and development of novel therapeutics for the treatment
of cancer is of high priority. Cannabinoids and their derivatives have been utilized for
their medicinal and therapeutic properties throughout history. Cannabinoid activity is
regulated by the endocannabinoid system (ECS), which is comprised of cannabinoid
receptors, transporters, and enzymes involved in cannabinoid synthesis and breakdown.
More recently, cannabinoids have gained special attention for their role in cancer cell
proliferation and death. However, many studies investigated these effects using in vitro
models which may not adequately mimic tumor growth and metastasis. As such, this
article aims to review study results which evaluated effects of cannabinoids from plant,
synthetic and endogenous origins on cancer development in preclinical animal models
and to examine the current standing of cannabinoids that are being tested in human
cancer patients.
Keywords: cannabinoids, cancer, in vivo, clinical studies, clinical trials, therapeutics, cancer models,
endocannabinoids
CANNABINOIDS AND CANCER
Cannabinoids are a class of hydrophobic molecules that typically bind to G-protein-coupled
cannabinoid receptors, cannabinoid receptor type 1 (CB1R) or cannabinoid receptor type 2
(CB2R). Endogenously synthesized cannabinoids (endocannabinoids), cannabinoid receptors,
and enzymes involved in cannabinoid formation and breakdown are collectively known as the
endocannabinoid system (ECS). This system has been shown to impact different neurological
and immunological processes (Zhu, 2006; Tanasescu and Constantinescu, 2010). Additionally,
numerous reports demonstrate that endocannabinoids and their putative receptors play a role in
the development of various malignancies (Fujimura et al., 1989). Many studies investigating the
effects of cannabinoids on tumor progression have been carried out in cell culture. However, due
to the complexity of the tumor microenvironment, these findings do not always translate to whole
animal models. As such, the goal of this review was to compile and analyze the results of studies
which evaluated effects of cannabinoids on cancer development in animal models (Table 1) and to
examine current knowledge regarding the impact of cannabinoids on tumor growth in humans.
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IN VIVO ANIMAL TUMOR MODELS
Animal tumor models have become a mainstay in preclinical
cancer research due to their ability to produce fairly
predictable tumor growth. The first tumor model used to
study tumorigenesis was the chemical carcinogenesis model.
This model employs the use of two known carcinogens, an
initiator and promotor. Initiators are typically employed in
a single dose to cause irreversible DNA damage. A promotor
is given in repeated doses to increase cell proliferation and
induce subsequent DNA damage (Kociba and Schwetz, 1982).
Implantable or grafted tumor models are also commonly used.
The major subtypes of these models are the (1) syngeneic
(allograft) model, in which tumor cell lines of host origin
are subcutaneously injected into immune-competent animals
and (2) the xenograft model, where cells distinct from the
implantation host are subcutaneously injected or grafted into
immune-deficient animals (Teicher, 2006). A more technically
challenging type of tumor grafting is that of the orthotopic
model in which tumor cells or tissues are grafted directly into
the organ or system of tumor origin (Peterson and Houghton,
2004). Patient derived xenografts offer high translational
value and are created when tumor tissue of human patients
is implanted into an immune-compromised animal (Jin et al.,
2010). Genetically engineered mouse models (GEMMs) are also
used to study carcinogenesis. In the GEMMs, transgenic mice
which over-express oncogenes or dominant negative tumor-
suppressor genes are often more susceptible to spontaneous
tumor induction (Sharpless and Depinho, 2006). Knockout
models in which the expression of specific genes is disabled
in animals exposed to carcinogens also provide valuable
information about mechanisms of tumor formation (Rosenberg
Abbreviations: ACF, aberrant crypt foci; 1-AG, 1- arachidonoyl glycerol; 2-AG, 2-
arachidonoyl glycerol; ABDH, alpha/beta-hydrolase domain; AEA arachidonoyl
ethanolamide; Akt, protein kinase B; Ang2, angiopoietin-2 Protein; AOM,
azoxymethane; BBB, blood-brain-barrier; CB1, cannabinoid receptor type 1;
CB2 cannabinoid receptor type 2; CBD, cannabidiol; CBG, cannabigerol;
CHOP10, C/EBP-homologous protein; COX-2, cyclooxygenase-2; CNS, central
nervous system; CRC, colorectal cancer; DEN, diethylnitrosamine; DMBA,
dimethylbenz[a]-anthracene; DNA, deoxyribonucleic acid; ECS, endocannabinoid
system; EGFR, epidermal growth factor receptor; EMT, endocannabinoid
membrane transporter; ER, estrogen receptors; ER-stress, endoplasmic reticulum
stress; ERK, extracellular signal-regulated kinase; FAAH, fatty acid amide
hydrolase; Fas, TNF receptor superfamily; GEMMs, genetically engineered mouse
models; GFAP, glial fibrillary acidic protein; GPR55, G-protein coupled receptor
55; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor
receptor type 2; ICAM-1, intracellular adhesion molecule-1; Id-1, inhibitor of
DNA binding protein; Jnk, c-jun N-terminal kinase; LC3, Microtubule-associated
protein 1A/1B-light chain 3;MAGL,monoacylglycerol lipase; MEF, mouse embryo
fibroblasts; MMP, matrix metalloproteinase; mTORC, mammalian target of
rapamycin complex; NMSC, non-melanoma skin cancer; NSCLC, non-small-cell
lung carcinoma; P-450, cytochrome P-450; pCXCR4, phospho-CXC chemokine
receptor 4; PPARγ, peroxisome proliferator-activated receptor gamma; PR,
progesterone receptor; p-S6, phospho-S6 ribosomal protein; ROS, reactive oxygen
species; S-100B, S100 calcium-binding protein B; SCLC, small-cell lung carcinoma;
THC, tetrahydrocannabinol; TIMP, tissue inhibitors of metalloproteinases; TMZ,
temezolamide; TPA, 12-O-tetradecanoylphorbol-13-acetate; TNBC, triple negative
breast cancer; TRB3, tribbles homolog protein 3; TRPM8, transient receptor
potential cation channel, subfamily M, member 8; TRPV1, transient potential
vanilloid receptor; UVB, ultraviolet light B; VEGF, vascular endothelial growth
factor; VEGFR, vascular endothelial growth factor receptor.
et al., 2009). Each of these tumor models is distinct and possess
advantages and disadvantages depending upon scientific and
clinical goals.
BRAIN CANCER
It is estimated that more than 23,000 individuals will be newly
diagnosed with central nervous system (CNS) cancers in 2016
(Siegel et al., 2016). There are many distinct neuronal and glial
tumor types that develop in the brain. Gliomas are a CNS
tumor subtype that are derived from glial tissue and account
for approximately 80% of all primary malignant brain tumors
(Ostrom et al., 2015). The prognosis for this neoplasm is poor
with an average 5-year survival rate of 5.1%. As such, novel
strategies are needed to impact current therapeutic approaches.
The ECS has been examined in clinical and preclinical glioma
models. Several studies show that glioma tissues from rodents
and humans express functional ECS components including the
CB1 and CB2 receptors (Sánchez et al., 2001; Moreno et al.,
2014). Furthermore, CB2 expression was found to be elevated
in high grade gliomas (Sánchez et al., 2001; Ellert-Miklaszewska
et al., 2007) Hence, a series of informative investigations
primarily conducted by the Guzman group, have examined the
effects of cannabinoids on glioma cell survival with the goal
of assessing the feasibility of developing these agents as novel
anti-neoplastics.
Numerous studies indicate that 19-tetrahydrocannabinol
(19-THC) is a potent inducer of glioma death in vivo. Utilizing
a C6 glioma cell xenograft model, it was demonstrated that
tumor growth was significantly reduced by 19-THC (Galve-
Roperh et al., 2000). Subsequent to orthotopic implantation of
the C6 cells the overall survival of 19-THC treated animals was
also increased. In vitro studies with the C6 cell line suggested
that the 19-THC-induced reduction in tumor growth occurred
as a consequence of increased ceramide synthesis and Erk
activation. Another study showed that 19-THC reduced the
growth of U87MG glioma xenografts (Jenkins et al., 2006).
Experimentation in the U87MG cell line determined that
ceramide accumulation and the induction of ER stress proteins
p8, CHOP10, and TRB3, were required for 19-THC-induced
death. The authors further demonstrated the importance of
p8 in tumor growth by utilizing transformed mouse embryo
fibroblasts (MEF) in which tumor development was reduced
in p8+/+ animals treated with 19-THC compared to vehicle
treated animals. In contrast, no significant difference in tumor
growth was observed in 19-THC or vehicle treated p8−/−
mice suggesting that p8 was needed for 19-THC-mediated
tumor death. In a subsequent study by this group, endoplasmic
reticulum stress-mediated autophagy and cell death was observed
in 19-THC treated glioma. Specifically, 19-THC caused an
increase in ER stress protein, TRB3, autophagy protein, LC3,
and apoptosis as well as a decrease in mTORC protein, p-
S6 in U87MG xenograft tumors (Salazar et al., 2009). This
pattern of protein expression was also observed in glioma
biopsies from 2 patients with glioblastomamultiforme treated via
intracranial administration with 19-THC. In vitro experiments
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TABLE 1 | Pre-clinical assessment of cannabinoids on tumor development.
Cancer
type
Model type
-cell line
Animal
species/strain
Cannabinoid Dose (route) Findings References
Glioma Xenograft—C6.9 Immune deficient
mice
Delta-9-THC 500 ug/day (p.t.) Decreased tumor size and
tumoral TIMP-1 expression
Blázquez et al., 2008b
JWH-133 50 ug/day (p.t.) Decreased tumor size and
tumoral TIMP expression,
ceramide inhibition increased
tumor growth
Xenograft—C6 Rag 2-/- mice WIN 55,212-2 50 ug/day (i.t.) Decreased tumor size Galve-Roperh et al., 2000
Delta-9-THC 500 ug/day (i.t.)
Orthotopic—C6 Wistar rat WIN 55,212-2 50–250 ug/day (i.t.) Increased survival
Delta-9-THC 500–2500 ug/day (i.t.)
Xenograft—U87MG Nude mice Delta-9-THC 15mg/kg/day (p.t.) Decreased tumor size, TUNEL
and p8 levels increased in
tumor
Jenkins et al., 2006
Orthotopic—U87MG CB-17 SCID mice KM-233 2–12mg/kg twice/day
(i.p.)
Decreased tumor size Gurley et al., 2012
Patient Derived
Xenograft
Athymic Balb/c
(nu/nu)
KM-233 12mg/kg, twice/day
(i.p.)
Tumor growth delay
Xenograft—C6 Rag 2-/- mice JWH-133,
WIN55,212-2
50 ug/day (i.t.) Decreased tumor size, effect of
JWH-133 prevented by CB2R
antagonism
Sánchez et al., 2001
Xenograft—
astrocytoma
cells
Rag 2-/- mice JWH-133 50 ug/day (i.t.) Decreased tumor size
Xenograft—U87MG Nude mice Delta-9-THC + TMZ 15 mg/kg THC,
5mg/kg TMZ (p.t.)
Greater reduction in tumor size
than THC or TMZ alone
Torres et al., 2011
Delta-9-THC + CBD 7.5mg/kg THC
7.5mg/kg CBD (p.t.)
Greater reduction in tumor size
than THC or CBD alone
Delta-9-THC + CBD
+ TMZ
3.7mg/kg THC
3.7mg/kg CBD
5.0mg/kg TMZ (p.t.)
Greater reduction in tumor size
than THC, CBD, or TMZ alone
Xenograft—T98G Nude mice Delta-9-THC + TMZ 15mg/kg THC
5.0mg/kg TMZ (p.t.)
Greater reduction in tumor size
than THC or TMZ alone
Xenograft—C6.9 Immune deficient
mice
Delta-9-THC 500 ug/day (p.t.) Decreased tumor growth and
tumor MMP-2 expression
Blázquez et al., 2008a
JWH-133 50 ug/day (p.t.) Decreased tumor size and
tumoral MMP-2 expression,
ceramide inhibition reduces
tumor growth
Xenograft—C6 Rag2-/- mice JWH-133 50 ug/day (i.t.) Decreased tumor size and
tumor expression of VEGFR
Blázquez et al., 2004
Xenograft—U87MG Athymic CD1 nude
(nu/nu)
CBD 0.5mg/day (p.t.) Decreased tumor size Massi et al., 2004
Xenograft—C6 cells
or primary
astrocytoma
Rag2-/- mice JWH-133 50 ug/day (i.t.) Decreased tumor size and
blood vessel size and
functionality
Blázquez et al., 2003
Orthotopic—U251 Athymic nude
(nu/nu)
CBD 15mg/kg (i.p.) Decreased tumor size,
decreased Id-1 and Ki67
expression in tumor
Aguado et al., 2007
(Continued)
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TABLE 1 | Continued
Cancer
type
Model type
-cell line
Animal
species/strain
Cannabinoid Dose (route) Findings References
Xenograft Athymic nude
(nu/nu)
CBD 15mg/kg (i.p.) Decreased tumor size,
Decreased Id-1 and K167
expression in tumor
Aguado et al., 2007
Xenograft—U87MG Nude mice Delta-9-THC 15mg/kg/day (p.t.) Reduced tumor size and
increased TRB1, LC3, caspase
3, and decreased S6 in tumors
Jenkins et al., 2006; Salazar
et al., 2009
Xenograft—T98G Athymic nude Delta-9-THC 1.5 or 15mg/kg/day
(p.t.)
Decreased tumor size and
anti-tumor effect reversed by
GRP55 knockdown
Sánchez et al., 2001
Orthotopic—3832 or
387 cells
Athymic nude
(nu/nu)
CBD 15mg/kg, 5 days/week
(i.p.)
Initial decrease in tumor size
followed by resistance
Singer et al., 2015
Orthotopic—GL261 C57Bl/6 CBD + Delta-9-THC 2mg/kg each (i.p.) CBD and THC enhanced killing
effect of ionizing radiation
Scott et al., 2014
Xenograft—glioma
stem cells
Athymic nude HU-210, JWH-133 30 uM treatment before
inoculation (p.t.)
Decreased tumor growth rate
and size decreased stem cell
markers increased
differentiation markers in tumor
Duntsch et al., 2006
Xenograft—C6.9 Immune deficient
mice
Delta-9-THC 500 ug/day (p.t.) Decreased tumor size and
MMP expression in tumor
Blázquez et al., 2008a
JWH-133 50 ug/day (p.t.) Decreased tumor size and
MMP expression in tumor,
ceramide inhibition prevented
tumor regression
Colon
cancer
Azoxymethane-
induced colon cancer
model
Male ICR mice CBD 5mg/kg 3x weekly (i.p.) Reduced aberrant crypt foci
(ACF), number of polyps and
tumors
Aviello et al., 2012
Azoxymethane-
induced colon cancer
model
Male ICR mice Cannabis extract rich
in CBD
5mg/kg (i.p.) Reduced aberrant crypt foci
(ACF), number of polyps and
tumors
Romano et al., 2014
Xenograft—HCT-116 Athymic nude
female
CBG 3 and 10mg/kg (i.p.) Reduced the growth Borrelli et al., 2014
Azoxymethane-
induced colon cancer
models
Male ICR mice 5mg/kg (i.p.) Reduced ACF, number of
tumor/mouse
Xenograft—HT-29 Nude mice HU-331 5mg/kg (i.p.) Reduced angiogenesis Kogan et al., 2006
Xenograft—HT-29 Nude mice HU-331 5mg/kg (i.p., s.c.,i.t.) Reduced tumor growth Kogan et al., 2004
General in vivo
toxicity
Sabra male mice,
SCID-NOD Mice
HU-331 7.5mg/kg (i.p.) Less toxicity than doxorubicin Kogan et al., 2007
Xenograft—HT-29 male nude mice 5mg/kg (i.p.) Reduced tumor growth and
less cardiotoxic than
doxorubicin
Colitisis induced
colon cancer model
(Azoxymethane,
AOM+dextran sulfate
sodium, DSS)
Male CD1 mice O-1602 3 mg/kg (i.p.) Reduced number and area of
tumors. Decreased histoscore
tumor burden and the
expression of proliferation
marker PCNA. Reduced key
mediators that link the
inflammation with colorectal
cancer such as: inflammatory
mediator TNF-α, and
oncogenic transcription factors
STAT3 and NFκB
Kargl et al., 2013
(Continued)
Frontiers in Pharmacology | www.frontiersin.org 4 October 2016 | Volume 7 | Article 361
Ladin et al. Cannabinoids as Anti-Cancer Agents
TABLE 1 | Continued
Cancer
type
Model type
-cell line
Animal
species/strain
Cannabinoid Dose (route) Findings References
Liver
Cancer
Xenograft—HepG2 Male athymic nude Delta-9-THC 15mg/kg (p.t.) Increased PPAR gamma
expression
Vara et al., 2013
JWH-015 1.5mg/kg (p.t.) PPAR-dependent reduction in
tumor growth
Xenograft—HepG2—
and
HuH-7
Athymic mice Delta-9-THC 15mg/kg (p.t.) Increase pAMPK, Reduced
pAKT, pS6.
Autogaphy-dependent
reduction in tumor growth
Vara et al., 2011
JWH-015 1.5mg/kg (p.t.)
Orthotopic—HepG2 Athymic mice Delta-9-THC 15mg/kg (i.p.) Decreased ascites formation,
increased pAMPK, Reduced
pAKT, pS6. Reduced alpha
fetoprotein levels
Vara et al., 2011
JWH-015 1.5mg/kg (i.p.)
Xenograft—Mz-ChA-1
(cholangiocarcinoma)
Nude mice AEA 10mg/kg (i.p.) GPR55-dependent reduction
of tumor growth
Huang et al., 2011b
O-1602 10mg/kg (i.p.)
Athymic mice AEA 10mg/kg (i.p.) Reduction in tumor growth and
VEGF expression
DeMorrow et al., 2008
Pancreatic Xenograft—MiaPaCa2 Nude mice Delta-9-THC 15mg/kg (p.t.) Reduced tumor growth Carracedo et al., 2006
JWH-133 1.5mg/kg (p.t.)
Orthotopic—
MiaPaCa2
WIN 55,212-2 1.5mg/kg (2 days) then
2.25mg/kg (2 days)
then 3.0mg/kg (10
days) (i.p.)
Reduced the growth and the
spreading of pancreatic tumor
cells
Breast Orthotopic—4T1.2
MVT-1
BALB/c CBD 10mg/kg (p.t.) Decreased tumor growth.
Decreased pAkt and EGFR
levels
Elbaz et al., 2015
Orthotopic—MVT-1 FVB
Xenograft—MBA-MD-
321
Athymic nu/nu CBD-rich extract 6.5mg/kg (i.t.) Decreased tumor growth Ligresti et al., 2006
Intraplanar—MBA-
MD-321
BALB/c CBD 5.0mg/kg (i.p.) Decreased tumor metastasis
Orthotopic—4T1 BALB/c CBD 1.0, 5.0mg/kg (i.p.) Decreased tumor growth and
metastasis
McAllister et al., 2011
Orthotopic—4T1 BALB/c CBD
O-1663
0.5, 1.0, 10mg/kg
CBD; 1.0mg/kg
O-1663 (i.p.)
Decreased tumor growth and
metastasis
Murase et al., 2014
Xenograft—MDA-MB-
231
Athymic nu/nu CBD
O-1663
0.5, 1.0, 10mg/kg
CBD; 1.0mg/kg
O-1663 (i.p.)
Decreased tumor metastasis.
O-1663 demonstrated greater
potency compared to CBD
Xenograft—4T1 BALB/c Delta-9-THC 12.5, 25, 50mg/kg
(s.c.)
Increased tumor growth and
Metastasis
McKallip et al., 2005
SCID-NOD Delta-9-THC 25mg/kg (s.c.) No effect on tumor growth
Xenograft
(intraplanar)—EMT6
BALB/c Delta-9-THC 25, 50mg/kg (i.p.) No effect on immune response
(Continued)
Frontiers in Pharmacology | www.frontiersin.org 5 October 2016 | Volume 7 | Article 361
Ladin et al. Cannabinoids as Anti-Cancer Agents
TABLE 1 | Continued
Cancer
type
Model type
-cell line
Animal
species/strain
Cannabinoid Dose (route) Findings References
Xenograft
(intraplanar)—4T1
BALB/c Delta-9-THC 25, 50mg/kg (i.p.) Decreased anti-tumor immune
response in CB2 dependent
manner
GEMM—MMTV-neu MMTV-neu Delta-9-THC 0.5mg/animal (p.t.) Decreased tumor growth,
multiplicity, and metastasis.
Decreased Akt levels
Caffarel et al., 2010
JWH-133 0.05mg/animal (p.t.)
Xenograft—N202.1 Athymic nu/nu Delta-9-THC 0.5 mg/animal (p.t.) Decreased tumor growth is Akt
mediated
JWH-133 0.05 mg/animal (p.t.)
Xenograft—MDA-
MB-231
SCID WIN-55,212-2,
JWH-133
5.0mg/kg (i.p.) Decreased tumor growth,
angiogenesis, and metastasis
Qamri et al., 2009
GEMM—MMTV-
PyMT
MMTV-PyMT WIN-55,212-2,
JWH-133
5.0mg/kg (i.p.) Decreased tumor growth and
progression
GEMM—MMTV-
PYMT
MMTV-PyMT JWH-015 5.0mg/kg (p.t.) Decreased tumor volume and
weight. Decreased CXCR4
phosphorylation
Nasser et al., 2011
Orthotopic—NT2.5 FVB
Orthotopic—
SUM159
Nude Mice JWH-015 10.0mg/kg (p.t.) Decreased tumor volume and
weight. Decreased EGFR and
IGF-1R signaling
McKallip et al., 2005
Orthotopic—MCF-7
Xenograft—MDA-
MB-231
Athymic nu/nu Synthetic CB2
agonist
2.0mg/kg (i.p.) Decrease tumor growth Morales et al., 2015
Allograft—TSA-E1 C57BL/6 Met-F-AEA 0.5mg/kg (i.p.) Decreased metastasis Grimaldi et al., 2006
Prostate Xenograft—LNCaP MF-1 nude CBD 1.0, 10, 100mg/kg
(i.p.)
Decreased tumor growth De et al., 2013
Xenograft—DU-145 MF-1 nude CBD 1.0, 10, 100mg/kg
(i.p.)
Potentiated tumor growth
Xenograft—PC-3 Athymic nu/nu JWH-015 0.15mg/kg (s.c.) Decreased tumor growth Olea-Herrero et al., 2009
Lung Xenograft—A549 NMRI nu/nu CBD 5.0mg/kg (s.c.) Decreased tumor growth,
plasminogen Activator
inhibitor- 1
Ramer et al., 2010a
Xenograft—A549 NMRI nu/nu CBD 5.0mg/kg (i.p.) Decreased tumor metastasis Ramer et al., 2010b
Xenograft—A549 NMRI nu/nu CBD 5.0mg/kg (i.p.) CBD upregulated ICAM-1 and
TIMP-1. ICAM-1 was required
for anti-metastatic properties
of CBD
Ramer et al., 2012
Xenograft—A549 NMRI nu/nu CBD 5.0mg/kg (i.p.) CBD decreased tumor growth
this was reversed by
co-administration with PPAR-γ
antagonist
Ramer et al., 2013
Allograft—LL2 C57BL/6 Delta-9-THC 5.0mg/kg (p.t.) No significant effect on tumor
growth
Martin-Banderas et al.,
2015
Allograft—3LL C57BL/6 Delta-9-THC 5.0mg/kg (i.p.) Increased tumor growth in
immunocompetent mode
Zhu et al., 2000
Xenograft—L1C2 BALB/c Delta-9-THC 5.0mg/kg (i.p.) No effect on tumor growth in
immunosuppressed model
(Continued)
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TABLE 1 | Continued
Cancer
type
Model type
-cell line
Animal
species/strain
Cannabinoid Dose (route) Findings References
Xenograft—A549 SCID Delta-9-THC 5.0mg/kg (p.t.) Decreased Tumor growth and
metastasis. Decreased Akt
Preet et al., 2008
Xenograft—3LL C57BL/6 Met-F-AEA 0.5mg/kg (i.p.) Decreased tumor metastasis Bifulco et al., 2001
Allograft—3LL C57BL/6 Met-AEA 5.0mg/kg (i.p.) Increased tumor growth in a
COX-2 dependent manner
Xenograft—L1C2 BALB/c Met-AEA 5.0mg/kg (i.p.) Increased tumor growth in a
COX-2 dependent manner
Gardner et al., 2003
Thyroid Xenograft—KiMol Athymic Nude VDM-11 5.0mg/kg (i.t.) Decreased tumor size Bifulco et al., 2004
AA-5-HT 5.0mg/kg (i.t.)
Met-AEA 0.7mg/kg (p.t.) Decreased tumor size,
anti-tumor effect blocked by
CB1 antagonist
Bifulco et al., 2001
Met-AEA 0.5mg/kg (p.t.) Decreased tumor size,
anti-tumor effect blocked by
CB1 antagonist, VEGF
expression decreased in tumor
Xenograft—ARO cells Balb/c (nu/nu) nude
mice
JWH-133 50 ug/ml (i.t.) CB2 overexpressing ARO cells
reduced tumor weight vs.
ARO-empty vector cells
Melanoma Xenograft—CHL-1 Athymic nude mice Delta-9-THC 15mg kg (p.o.) Reduced tumor growth, Ki67
and increased TUNEL positive
cells
Armstrong et al., 2015
Xenograft—HCmel12
(intracutaneous)
Cnr1/2−/− mice
were crossed into
the Hgf-Cdk4R24C
melanoma mouse
model to generate
mice with a dark
skin phenotype
which develop CB1
and CB2
receptor-deficient
melanomas.
Delta-9-THC 5mg/kg (s.c.) CB receptors-dependent
reduction in tumor growth
Glodde et al., 2015
Xenograft—B16 C57BL/6 mice and
Nude
WIN-55,212–2 50 ug/day (p.t.) Reduced tumor growth, cell
proliferation, apoptosis, and
angiogenesis
Blázquez et al., 2006
JWH-133
Xenograft B–16
(intraplantar)
C57BL/6 mice WIN-55,212–2 50 ug/day (p.t.) Reduced metastasis in lung
and liver
JWH-133 JWH-133
NMSC Xenograft—PDV.C57 Nude (NMRI nu)
mice
WIN-55,212-2 6.7 ug/ul (flow
pump—0.52 uL/h
(11 days)
Inhibited skin tumor growth,
angiogenesis and EGFR
activation
Casanova et al., 2003
JWH-133
DMBA/TPA skin
carcinogenesis model
Female ICR mice JWH-018 0.02 and 0.2 uM (t.o.) Inhibited inflammation,
promotion of skin papillomas,
tumor incidence
Nakajima et al., 2013
JWH-122 0.2 and 2 uM (t.o.)
JWH-210 0.2 and 2 uM (t.o.)
p.t., peritumor; i.t., intratumor; i.p., intraperitoneal; s.c., cubcutaneous; t.o., topical; p.o. oral.
Frontiers in Pharmacology | www.frontiersin.org 7 October 2016 | Volume 7 | Article 361
Ladin et al. Cannabinoids as Anti-Cancer Agents
with the U87MG cell line suggested that 19-THC mediated
activation of TRB3 was a critical link between the ER stress
and autophagy pathways as TRB3 activation was needed for
inactivation of Akt and the mTORC1 complex. Other reports
indicated that the administration of 19-THC improves the
therapeutic outcome of the clinically utilized glioma anti-
neoplastic, temezolamide (TMZ) (Torres et al., 2011). In this
study, 19-THC significantly reduced the growth of U87MG
xenograft tumors treated with TMZ when compared to TMZ
or 19-THC alone. Similarly, administration of 19-THC +
cannabidiol (CBD) or 19-THC + CBD + TMZ significantly
reduced tumorigenesis compared to the individual drugs (Torres
et al., 2011). The combined drug regimen was associated
with prevalent LC3 expression and cell death in U87MG
tumors. The mechanism of cell death was also examined in
cultured U87MG cells where inhibition of ceramide synthesis
and autophagy prevented cellular cytotoxicity (Torres et al.,
2011). Since each of these studies also determined that the
cytotoxic effect of 19-THC was dependent on cannabinoid
receptors, the findings of these reports indicate that ceramide
synthesis, ER stress, autophagy and cannabinoid receptor
activation are likely shared mechanism of 19-THC-induced
glioma death.
Cannabinoid regulation of matrix remodeling proteins
may also play a role in its anti-tumor activity. Matrix
metalloproteinases (MMP) can promote or prevent tumor
invasion and metastasis by degrading extracellular matrix
and other cell-associated proteins (Lukaszewicz-Zajac et al.,
2014). In addition, the effects of MMPs are counteracted by
tissue inhibitors of metalloproteinases (TIMPs). MMPs/TIMPs
also directly regulate tumor growth, tumor apoptosis and
angiogenesis. An examination of the effect of 19-THC on C6.9
cell xenograft growth showed that animals treated with 19-
THC contained smaller tumors with reduced MMP-2 expression
in contrast control group animals (Blázquez et al., 2008a).
19-THC also reduced tumor growth and the expression of
MMP-2 in tumors of 19-THC-treated patients. Cell culture
studies with C6.9 cells confirmed that MMP-2 expression and
cell viability were decreased as a result of 19-THC exposure
(Blázquez et al., 2008a). A different study by this research
group also indicated selective participation of TIMP-1 in the
anti-neoplastic activity of 19-THC (Blázquez et al., 2008b).
Similar to MMPs, TIMPs have both a positive and negative
impact on tumor growth (Lukaszewicz-Zajac et al., 2014). In
C6.9 xenografts, 19-THC decreased tumor development and
tumoral TIMP-1 but had little impact on TIMP-2 or TIMP-3
expression. Selective TIMP-1 downregulation was also observed
in patient tumor samples subsequent to19-THC administration.
C6.9 cell culture studies showed that19-THC decreased TIMP-1
expression by increasing ER stress and ceramide synthesis and
also demonstrated that 19-THC reduced C6.9 cell migration
(Lukaszewicz-Zajac et al., 2014). These studies suggest that
downregulation of MMP-2 and TIMP-1 is important for 19-
THC regulation of tumor size, however additional work is needed
to reveal whether the reduction in these matrix modulating
proteins also alters the metastatic and invasive behavior of tumor
cells in vivo.
An investigation of the effects of 19-THC on human
glioblastoma-T98G xenografts demonstrated concentration-
dependent effects with low 19-THC concentrations causing
a modest increase in tumor growth and high 19-THC
concentrations promoting tumor cell death (Sánchez et al.,
2001). Experiments in cultured T98G cells suggested that this
effect was mediated by the formation of a functional dimeric
complex between GPR55 and CB2 receptors such that low
concentrations of 19-THC activated the CB2 receptor and Erk
expression thereby promoting tumor cell growth. However, in
the presence of high19-THC concentrations,19-THC inhibited
GPR55 which blocked the CB2 receptor and Erk activation
thereby inhibiting tumor cell growth. This finding is consistent
with reports showing that the putative G-protein-coupled
cannabinoid receptor, GPR55, is overexpressed in cancers and
promotes carcinogenesis (Falasca and Ferro, 2016).
Most clinically available cancer chemotherapeutic agents
demonstrate significant toxicity toward cancer and normal cells.
This lack of selectivity often produces undesirable side effects that
limit its therapeutic utility. 19-THC preferentially induced cell
death in tumorigenic compared to non-tumorigenic astrocytes
(Jenkins et al., 2006). Moreover, in non-tumor bearing rats, 19-
THC (2500µg) exhibited limited toxicity and did not affect
animal survival, health, behavior or hematopoietic parameters
(Galve-Roperh et al., 2000). These findings suggest that19-THC
will cause limited adverse effects thereby making this compound
an attractive candidate for therapeutic use. Furthermore, the
anti-emetic, appetite stimulating and analgesic effects of 19-
THC and other cannabinoids can provide relief for important
co-morbidities commonly associated with cancer and cancer
chemotherapy.
Cannabidiol (CBD) is a non-psychotropic phytocannabinoid
whose effect on tumor growth is being extensively explored.
CBD significantly reduced U87MG xenograft growth when
compared to vehicle control animals (Massi et al., 2004). An
in vitro examination of the mechanism of action suggested that
the induction of reactive oxygen species (ROS) and activation
of the CB2 receptor was involved in the anti-tumor effect.
However, unlike 19-THC, CBD toxicity did not appear to be
regulated by CB1 or ceramide. Furthermore, in an orthotopic
and subcutaneous tumor model, CBD significantly decreased
U251 cell tumor growth (Soroceanu et al., 2013). In tumors
generated by both methods, the expression of the proliferation
marker, Ki67, and inhibitor of DNA binding (Id-1) protein
were reduced. Id-1 is a transcription factor that prevents tumor
cell differentiation and its expression is elevated in highly
aggressive tumors (Ling et al., 2006). Cell culture studies showed
that CBD inhibited Id-1 expression which occurred coincident
with a reduction in U251 cell invasiveness (Soroceanu et al.,
2013). A follow up study by this group demonstrated that
CBD inhibited tumor growth and increased the survival of
animals orthotopically implanted with primary 3832 and 387
glioblastoma cells (Singer et al., 2015). The reduction in tumor
size was accompanied by decreased expression of Id-1 and Sox-
2 indicating a reduction in tumor aggressiveness. Continued
administration of CBD in this model resulted in reduced
responsiveness to CBD, increased antioxidant response gene
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expression and upregulated expression of mesenchymal markers
in the tumors. Investigation of the in vitromechanism suggested
that resistance to CBD was primarily caused by activation of
SCL7A11 (a transcriptional target of Nrf2) antioxidant signaling
as inhibition of this target decreased tumor cell survival and
augmented the antitumor activity of CBD. A different study
revealed that CBD potentiated the killing effect of ionizing
radiation (IR), a common clinical therapy for glioblastoma.
Using an orthotopic xenograft model, CBD + 19-THC + IR
significantly decreased the size of GL261 gliomas compared to
CBD + 19-THC or IR alone (Scott et al., 2014). Increased
TUNEL positive cells in tumors isolated from animals exposed to
CBD + 19-THC + IR implicated cell death as the mechanism
of tumor growth inhibition. Thus, the antitumor activity of
19-THC and CBD has been demonstrated in different in vivo
tumor models and the diverse pathways by which these agents
elicit death appear to favor co-administration with other
chemotherapeutic agents.
Numerous studies suggest that synthetic cannabinoids such
as JWH-133, WIN 55,212-2 and HU-210 are promising
chemotherapeutic agents for treatment of gliomas. In murine C6
xenografts, the growth of glioma solid tumors was significantly
inhibited by JWH-133 compared to control group animals
(Sánchez et al., 2001). This effect was found to be mediated
by the CB2 but not the CB1 receptor. In the same animal
model, JWH-133 also inhibited the growth of human glioma
cells. Examination of the mechanism of cytotoxicity in cultured
C6 cells showed that ceramide synthesis was needed for JWH-
133-mediated tumor cell death. Later studies by this group
validated the in vitromechanism by demonstrating that blockade
of ceramide synthesis in vivo decreased the anti-tumor activity of
JWH-133 (Blázquez et al., 2008a,b). These studies also revealed
that ceramide was involved in JWH-133-induced suppression
of the invasion associated proteins, MMP-2 and TIMP-1.
The combined reports suggest that the induction of ceramide
synthesis by JWH-133 causes a reduction tumor cell survival and
invasion.
The effect of synthetic cannabinoids on angiogenesis was also
examined. JWH-133 reduced the growth of C6 gliomas that was
accompanied by a decrease in tumoral, pro-angiogenic VEGF
and VEGFR (Blázquez et al., 2004). It was determined that
VEGFR levels were also downregulated in glioma biopsies from
patients treated with 19-THC. In vitro studies with C6 cells
demonstrated that both JWH-133 and WIN 55,212-2 decreased
VEGFR2 phosphorylation and VEGF levels by increasing
ceramide production. The reduction in VEGF signaling by the
cannabinoids was also dependent on CB1 and CB2 receptors.
A more detailed examination of the effect of cannabinoids on
angiogenesis showed that JWH-133 decreased the permeability
of tumor localized blood vessels as well as the growth of C6 and
patient-derived glioma cells in xenograft tumor studies (Blázquez
et al., 2003). Consistent with these results, the mRNA expression
of the angiogenesis and metastasis-promoting proteins VEGF,
Ang2 and MMP-2 were decreased by JWH-133. Furthermore,
in vitro studies using HUVEC cells demonstrated that JWH-
133 inhibited endothelial cell migration and initiated death that
was reversed by antagonism of CB1 and CB2 receptors. The
findings of these reports indicate that cannabinoid prevention of
angiogenesis is reliant on ceramide production and cannabinoid
receptor activation.
Accumulating evidence suggests that a subpopulation of
brain tumors originate from pluripotent stem-like cells (Singh
et al., 2004). These undifferentiated cells are often associated
with poor prognosis and highly aggressive tumor phenotypes
whereas well-differentiated glial cells are typically less aggressive
(Wan et al., 2011). As such, the stem-like population of
U87MG cells and human gliomas were treated with JWH-133
or HU-210 and then subcutaneously implanted to examine
the effect of cannabinoids on this tumor cell subtype (Aguado
et al., 2007). Cannabinoid treated cells formed smaller tumors
which contained low levels of stem-like stage proteins such
as nestin and high levels of differentiation-associated proteins
including β-tubulin III and S-100β. Consistent with these
findings, JWH-133 and HU-210 decreased the expression of
nestin and increased the expression of GFAP, S-100β and
β-tubulin III in cultured stem-like glioma cells. Hence it appears
that the anti-neoplastic activity of the synthetic cannabinoids
may be attributed to their ability to prevent tumor cell
survival, invasion, and angiogenesis while promoting tumor cell
differentiation.
KM-233 is a synthetic cannabinoid that signals through
CB1 and CB2 receptors and is a derivative of 18-THC
(Krishnamurthy et al., 2008). The anti-neoplastic activity of KM-
233 was examined in an orthotopic U87MG cell tumor protocol
where a significant reduction in tumor size occurred (Gurley
et al., 2012). These results were verified in a xenograft tumor
study using patient-derived glioblastoma multiforme tissue.
In vitro studies showed that KM-233 induced U87MG death
was prevented by antagonizing the CB1 receptor. A subsequent
study by this group confirmed the anti-tumor activity of KM-
233 against U87MGxenograft tumors and also demonstrated that
KM-233 produced minimal damage to neuronal tissue within the
therapeutic dosage range (Duntsch et al., 2006). As such, KM-233
may be an effective agent against glioma with an acceptable safety
profile similar to other cannabinoids.
The bulk of our knowledge about the effect of cannabinoids
on cancer growth in in vivo models is derived from the
aforementioned glioma studies. Much of this work demonstrated
potent antitumor activity, confirmed in vitro mechanisms of
cannabinoid antitumor action and provided evidence that
these molecules were minimally toxic and therefore paved the
way for execution of a clinical study with a small number of
glioma patients (Clinical trial ID# NCT01812603). However,
additional experimentation in animals is needed to define the
pharmacokinetic properties of cannabinoids before large scale
human studies are conducted. It will be particularly important
to examine drug accumulation in tumors and drug disposition
in body compartments subsequent to drug administration via
different routes as most of the glioma studies conducted thus far
employ intra/peri-tumor drug delivery. Such investigations may
identify more clinically convenient routes of administration,
establish the extent of drug stability and metabolism while
providing clues about potential adverse effects of these
agents.
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DIGESTIVE SYSTEM CANCER
Digestive system cancers include colon, stomach, liver, and
pancreatic cancer. In the United States, these combined
malignancies account for the highest incidence of cancer besides
skin cancer and are the second leading cause of death for both
sexes. In 2016, an estimated 304,930 new cases of digestive system
cancer will be diagnosed in the US with 153,030 estimated deaths
(Siegel et al., 2016).
Colorectal Cancer
Colorectal cancer (CRC) is the most lethal type of digestive
cancer followed by pancreatic and then liver cancer. Recent
studies advocate that the ECS plays a critical role in CRC
development and is therefore considered an appropriate target
for CRC inhibition. The levels of the endocannabinoid,
anandamide (AEA), the enzymes participating in AEA
biosynthesis and degradation, as well as its molecular target
CB2, are elevated in tumor specimens of CRC patients (Cianchi
et al., 2008; Chen et al., 2015). Furthermore, there was a positive
correlation between CB2 receptor expression and human colon
cancer growth. Consistent with this finding, the CB2 receptor
was a poor prognostic marker in advanced stages of colon cancer
(stage III and IV) (Martinez-Martinez et al., 2015). Hence, the
ECS may significantly impact colon tumor progression. The
anti-cancer activities of phyto- and synthetic cannabinoids
in colon cancer animal models have also been reported. In
chemically-induced azoxymethane (AOM) colon carcinogenesis,
the phytocannabinoids, CBD and Cannabis sativa extract (which
contains high CBD content, one of the main components of the
botanical drug, Nabiximols) reduced aberrant crypt foci (ACF)
formation and the number of precancerous polyps and tumors
(Aviello et al., 2012; Romano et al., 2014). In vitro experiments
in the same studies suggested that the cytotoxicity was mediated
by CB1, TRPV1, and PPARγ (CBD and Cannabis extract) or
CB2 (Cannabis extract) (Aviello et al., 2012; Romano et al.,
2014). Furthermore, the non-psychoactive phytocannabinoid,
cannabigerol (CBG), reduced the growth and development of
HCT-116 xenografts and AOM-induced colon cancer formation.
Using the HCT-116 cell lines, cell death was prevented by
blocking TRPM8 but not CB1, CB2, or TRPV1 receptors
(Borrelli et al., 2014). Synthetic cannabinoids also showed anti-
cancer activity in different animal models. HU-331, a quinone
compound synthesized from cannabidiol, reduced angiogenesis
and tumor growth in a HT-29 xenograft model (Kogan et al.,
2004, 2006). In nude mice xenografts with HT-29 cells, HU-
331 also showed greater inhibition of tumor growth than the
clinically utilized chemotherapeutic, doxorubicin (Kogan et al.,
2007). Moreover, a comparative study utilizing multiple animal
models showed that HU-331 exhibited less cardiotoxicity than
doxorubicin. In a different study, O-1662 an analog of abnormal
cannabidiol, reduced the number and size of tumors formed
by AOM + dextran sulfate sodium in the colitis-induced
colon cancer model. This activity was accompanied by reduced
inflammation, proliferation, and induction of apoptosis in the
tumor tissue (Kargl et al., 2013). Although numerous studies
tested the effect of cannabinoids and their derivatives in different
CRC models, reports that utilize agents which bind selectively
to CB1 or CB2 receptors are lacking. As such, the direct role of
cannabinoid receptor activation in the context of CRC treatment
has not been addressed in vivo.
Liver Cancer
There are two major types of liver cancer, hepatocellular
carcinoma (HCC; also known as hepatoma), which originates in
hepatocytes and accounts for approximately 75% of liver cancers
and cholangiocarcinoma, which develops within the bile ducts
of the liver (Huang et al., 2011a). Xu et al. found that the
expression of both CB1 and CB2 receptors was increased in HCC
tissues and was strongly associated with improved prognosis
and disease-free survival rates (Xu et al., 2006). Conversely,
Mukhopadhyay et al. reported that CB1 receptors promote
the initiation and progression of diethylnitrosamine (DEN)-
induced HCC in mice (Mukhopadhyay et al., 2015). Hence, it
is appropriate to investigate whether cannabinoid receptors are
suitable targets for treatment of liver cancer. Phytocannabinoid,
19-THC, and synthetic CB2 receptor agonist, JWH-015 reduced
the growth of HepG2 and HuH-7-derived tumor xenografts
and diminished ascites development in an orthotopic model
of HCC. The anti-tumor activities of 19-THC and JWH-015
in hepatocellular carcinoma cell lines (HepG2 and HuH-7)
were mediated by the activation of CB2 receptors followed by
increased ceramide, ER-stress, PPAR-γ activity, and eventually
the induction of autophagy (Vara et al., 2011, 2013). Furthermore,
the endocannabinoid, AEA, reduced the growth of Mz-ChA-1-
derived cholangiocarcinoma xenografts and downregulated the
tumor expression of angiogenic factors, VEGF-C, VEGF-R2, and
VEGF–R3 in AEA-treated tumors. The anti-neoplastic activity of
AEA was mediated by GPR55 receptors (in vivo and in vitro),
activation of Wnt/JNK signaling (in vitro), and recruitment of
the Fas death receptor into lipid rafts (in vitro) (DeMorrow et al.,
2008; Huang et al., 2011b). These studies provide strong support
that phyto, synthetic, and endogenous cannabinoids confer anti-
proliferative effects on liver tumor cells, however, in these
reports xenografts are the primary model utilized. Additional
insight would be gained by assessing the effect of cannabinoids
on HCC using chemical carcinogenesis models which evaluate
tumor growth with clinically relevant carcinogens in their native
microenvironment.
Pancreatic Cancer
The ECS plays an active role in pancreatic carcinogenesis.
It was reported that CB1 and CB2 receptor expression was
elevated in human pancreatic tumors when compared to normal
pancreas (Carracedo et al., 2006; Michalski et al., 2008). Although
the levels of endocannabinoids, AEA, 1-AG, and 2-AG were
unchanged in pancreatic cancer compared to normal human
pancreas, high levels of CB1 receptor expression and low levels
of endocannabinoid degrading enzymes, FAAH and monoacyl
glycerol lipase (MAGL), were associated with shorter survival
(Michalski et al., 2008). On the other hand, Carracedo et al.,
demonstrated that 19-THC and JWH-133 reduced growth
of MiaPaCa2-derived xenografts. Additionally, WIN-55,212-
2 reduced the growth of orthotopically implanted MiaPaCa2
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pancreatic tumors and prevented the spread of tumor cells to
distal organs (Carracedo et al., 2006). In vitro studies showed that
the anti-proliferative activity of the cannabinoids was mediated
by the activation of CB2 receptors followed by de novo synthesis
of ceramide and the induction of ER-stress (Carracedo et al.,
2006).
Collectively, the ECS plays an important role in the
progression of digestive cancers including colon, liver, and
pancreatic cancers. Cannabinoid receptor expression is elevated
in tumors when compared to normal tissues, indicating that
endogenous cannabinoids have cancer promoting activity.
However, preclinical studies revealed that exogenous synthetic,
phyto-, and endo- cannabinoids reduced tumor incidence,
growth, and angiogenesis. Although sufficient evidence is not
available to explain this effect, these seemingly opposing events
may be explained by the biphasic effect of cannabinoids.
Whereas low cannabinoid concentrations (<10 uM) increase
tumor progression, high concentrations (>10 uM) reduce cancer
cell proliferation (Martinez-Martinez et al., 2015). Further
research is required to uncover potential in vivo biphasic effects
and determine the optimum drug concentrations needed to
prevent pancreatic cancer growth. Moreover, since the number
of pancreatic tumor studies with cannabinoids is extremely
limited, more research is required to demonstrate cannabinoid
efficacy.
BREAST CANCER
Breast cancer is the most commonly diagnosed cancer in women
and the second leading cause of female cancer deaths in the
United States (Siegel et al., 2016). Risk factors for developing
this type of cancer include: being of the female sex, having a
family history of this disease, obesity, and menopause-associated
hormone replacement (Kaminska et al., 2015). Recent research
suggested that cannabinoids and the ECS played a role in
breast cancer progression and may possess therapeutic potential
(Caffarel et al., 2012).
Breast cancer can be divided into three sub-types: hormone
sensitive breast cancer, which expresses estrogen receptors
(ER) and/or progesterone receptors (PR); HER2-positive breast
cancer, which expresses human epidermal growth factor receptor
(ErbB2, a member of the EGFR family); and triple negative
breast cancer (TNBC), a type of breast cancer which is difficult
to treat due to the lack of ER, PR, and HER2 expression.
Cannabinoid receptor expression differs between these breast
cancer sub-types. CB1 receptors were reported to be present
in 28% of all breast carcinoma patients, with 14% being HER2
positive. On the other hand CB2 receptors were found in 72% of
breast carcinomas and 91% of these tumors were HER2 positive,
suggesting a possible link between HER2 and CB2 expression
(Qamri et al., 2009; Caffarel et al., 2010; Pérez-Gómez et al.,
2015). Of interest, a correlation between CB2 receptor expression
and breast cancer aggressiveness has been suggested (Caffarel
et al., 2006). As such, the effects of cannabinoids on breast tumor
growth and metastasis using in vivo models has helped elucidate
their therapeutic and prognostic potential.
Phytocannabinoids such as 19-THC and CBD induce both
breast cancer regression and progression in vivo, indicating that a
complex interaction between these compounds and cancer exists.
CBD was shown to decrease tumor growth in multiple breast
cancer models including: two orthotopic models, one genetically
engineered mouse model (GEMM) and one TNBC xenograft
model (Ligresti et al., 2006; McAllister et al., 2011; Murase
et al., 2014; Elbaz et al., 2015). CBD significantly decreased
the incidence of lung metastasis in TNBC xenograft metastatic
and orthotopic mouse models. Furthermore, two of these
studies which used genetically engineered and xenograft models
proposed that CBD elicited these effects by inhibiting EGFR
activation, cytokine secretion, and Akt expression (McAllister
et al., 2011; Elbaz et al., 2015). The CBD derivative, O-1663,
was also shown to decrease TNBC xenograft growth through a
mechanism requiring the generation of oxidative stress (Murase
et al., 2014). Consistent with the findings for CBD, 19-THC
impaired tumor growth, multiplicity and metastasis in both
HER2 positive MMTV-neu mice (a GEMM) and HER2 positive
xenografted mice (Caffarel et al., 2010). This group also found
that downregulation of pro-tumorigenic Akt was involved in the
anti-proliferative effects of 19-THC (Caffarel et al., 2010). In
contrast, phytocannabinoids also promoted tumor development.
The Nagarkatti group found that mice implanted with 4T1 cells
that were treated with19-THC displayed greater tumorigenicity
and metastatic potential by inhibiting host anti-tumor immune
responses (McKallip et al., 2005). Indeed, phytocannabinoid-
induced immune suppression has been reported to be mediated
by the CB2 receptor in similar tumor models (Zhu et al., 2000).
Synthetic cannabinoid receptor agonists have also been
utilized to elucidate the role of CB1 and CB2 receptors in breast
cancer growth. Activation of CB1/CB2 receptors using WIN-
55,212-2 led to significant decreases in tumor growth and lung
metastasis in a TNBC xenograft and a genetically engineered
MMTV-PyTV (mouse mammary tumor virus encoding polyoma
virus middle T antigen) mouse model (Qamri et al., 2009).
Furthermore, selective CB2 receptor activation with JWH-133
inhibited the growth of tumors and decreased metastasis in
MMTV-PyTVmice, HER2 positive MMTV-neu mice andMDA-
MB231-derived xenografts (Qamri et al., 2009; Caffarel et al.,
2010; Morales et al., 2015). Follow-up in vitro studies performed
in MDA-MB231, MDA-MB468 and N202.1 cells also suggested
that CB2 receptor activation by synthetic cannabinoids such
as JWH-133 downregulated pro-tumorigenic prostaglandin E2
(PGE2) or Akt similar to phytocannabinoids (Qamri et al., 2009;
Caffarel et al., 2010). Another CB2 receptor agonist, JWH-
105, was found to inhibit tumor growth in a NT2.5-orthotopic
mouse model and the MMTV-PyMTmodel and this observation
corresponded to decreased pro-metastatic phospho-CXCR4 and
phospho-ERK levels in vivo and in vitro (Nasser et al., 2011).
Additionally, activation of CB2 receptors by a similar compound,
JWH-015, was also found to decrease tumor growth and weight
in both, ER- positive and ER- negative orthotopic models
(Elbaz et al., 2016). JWH-015 treated mice exhibited decreased
EGFR and IGF-1R signaling and Akt expression (Elbaz et al.,
2016). Finally, the synthetic and metabolically stable analog of
AEA, 2-methyl-2’F-anandamide (Met-F-AEA), was also shown
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to decrease lung metastasis in TSA-E1 cell-derived xenografts
(Grimaldi et al., 2006). For the most part, in vivo studies indicate
that phyto-, synthetic- and endo- cannabinoids suppress tumor
development in hormone receptor positive, EGFR positive and
triple negative breast cancer animal models. However, additional
animal studies are needed to understand how cannabinoid
regulation of the immune system impacts breast tumor
growth.
PROSTATE CANCER
Carcinoma of the prostate is the development of malignant
cells within the male reproductive prostate gland. It is the
most commonly diagnosed cancer in all men with an estimated
180,000 new cases in 2016 (Siegel et al., 2016). This cancer type
is also the second leading cause of cancer deaths in men, which
primarily appears to be a result of late detection. Risk factors for
developing this disease are advanced age, family history, and race.
Cannabinoids and their receptors have shown promise as
potential therapeutics in prostate cancer. CB1 and CB2 receptor
expression was shown to be elevated in prostate cancer compared
to normal prostate tissue and are suggested to be positively
correlated with poor disease outcome (Sarfaraz et al., 2005;
Chung et al., 2009). Prostate cancer progression depends on
androgen activity and while the ECSmay influence this signaling,
the interplay between these systems in the context of cancer is
poorly understood (Sánchez et al., 2003a,b). Although numerous
studies have evaluated the effect of cannabinoids on prostate
cancer in cell culture studies, relatively few reports have
determined if these effects occur in in vivo animal models.
Di Marzo’s group found that cannabis extracts enriched with
CBD effectively decreased tumor growth in androgen receptor
positive LNCaP xenografts but potentiated tumor growth of
androgen receptor negative DU-145 xenografts (De et al., 2013).
Furthermore, in vitro experiments using PC-3, DU-145, 22RV1,
and LNCaP cell lines in this study found that CBD decreased
androgen receptor expression suggesting that crosstalk between
the CBD and androgen signaling pathways may affect tumor
growth. CBD also significantly increased the generation of ROS
and pro-apoptotic CHOP10 expression in these four prostate
cancer cell lines (De et al., 2013). Similarly, JWH-015 led
to decreased tumor proliferation in PC-3 derived xenografts.
These anti-proliferative effects were examined in vitro and were
suggested to be mediated by CB2 induced synthesis of ceramide
(Olea-Herrero et al., 2009). While these studies show a promising
role for cannabinoids in targeting prostate cancer, more research
is needed to definitively establish cannabinoid efficacy in vivo and
the importance of androgen receptor signaling in this system.
LUNG CANCER
Lung cancer is the most deadly neoplasm in both males and
females in the United States with a death toll anticipated to
exceed 150,000 individuals in 2016 (Siegel et al., 2016). The two
major types of lung cancer are small-cell lung cancer (SCLC) and
non-small-cell lung cancer (NSCLC). Risk factors for developing
this disease are tobacco smoking, genetic predisposition, and
exposure to radon gas. Survival figures from this disease
powerfully demonstrate the need for novel interventions. As
such, cannabinoids have been evaluated in vivo for their efficacy
against lung cancer.
CB1 receptors were expressed in 24% human NSCLC tissues,
while CB2 receptor expression was found in 55% of NSCLC,
suggesting a role for CB-receptors in tumor development (Preet
et al., 2011). Cannabinoids such as 19-THC, CBD and Met-
AEA elicited different effects in lung cancer animal models.
CBD administration to mice with A549 cell xenografts decreased
tumor growth, invasion and metastasis (Ramer et al., 2010a,b,
2012). Follow up in vitro experiments using A549, H358, and
H460 lung cancer cell lines suggested that the anti-metastatic
effect of CBD was mediated by upregulation of intracellular
adhesionmolecule-1 (ICAM-1), an anti-metastatic protein which
has been suggested to suppress tumor growth via an immuno-
surveillance mechanism (Wolfram et al., 2000; Ramer et al.,
2012). In another study, CBD exhibited anti-tumor effects that
were reversed by co-administration of a PPARγ antagonist in
vivo (Ramer et al., 2013). Similarly, Preet et.al. found that
the phytocannabinoid, 19-THC, downregulated Akt in A549-
derived xenografts, which corresponded with decreased tumor
growth and metastasis (Preet et al., 2008). In contrast, Zhu
et al. showed that 19-THC increased the tumorigenicity of
3LL lung cancer cells in allografted immunocompetent mice
and demonstrated that CB2 mediated inhibition of anti-tumor
lymphocyte activity was the primary mechanism for accelerated
tumor growth (Zhu et al., 2000). Furthermore, these investigators
and the Arevalo group found that 19-THC administration had
no effect on tumor growth in xenografted immunodeficient mice
(Zhu et al., 2000; Martin-Banderas et al., 2015). Stable analogs of
AEA also showed differential effects on lung cancer progression
in vivo. The Dubinett group found that met-AEA increased
tumor growth in a xenograft and allograft murine model and
that COX-2 inhibition abrogated these effects (Gardner et al.,
2003). Conversely, Bifulco et al. found that met-F-AEA treatment
decreased tumor metastasis in a 3LL cell-derived xenograft
model (Bifulco et al., 2001). These studies suggest that the ECS
plays a role in both lung cancer progression and suppression.
Consequently, several of these studies indicate that anti-tumor
immunity is suppressed by certain cannabinoids, exacerbating
tumor growth in immune-competent animals. As such, exploring
the interplay between the immune system, the ECS and lung
cancer development may be critical in determining whether
cannabinoids are suitable for lung cancer treatment.
THYROID CANCER
Thyroid cancer is the most frequently diagnosed endocrine
malignancy in the United States. It is estimated that more than
64,000 new cases will be identified and 1900 deaths will result
from this disease (Siegel et al., 2016). Although the death rate
is relatively low compared to other types of cancer, therapeutic
options are needed for aggressive forms of this disease whose
lethality is thought to be associated with the differentiation
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state of the tumor (Lee et al., 2016). Relatively few studies
have examined the effect of cannabinoids on thyroid tumor
development in vivo, but these reports showed that the ECS was
expressed and was capable of modulating tumor growth (Portella
et al., 2003; Bifulco et al., 2004; Shi et al., 2008). For example,
the activity of a variety of ECS modulators was examined in
KiMol thyroid cells which generate undifferentiated tumors
in xenograft models (Bifulco et al., 2004). In this study, the
endogenously synthesized cannabinoid, 2-AG reduced thyroid
tumor development. Similarly, agents that inhibited the EMT
(VDM-11) and blocked AEA hydrolysis (AA-5HT) prevented
in vivo tumor growth. Also, the metabolically stable molecules,
arvanil and met-F-AEA also produced a significant reduction
in tumor growth. The results of this study suggested that
manipulation of the EC system was a viable option to prevent
propagation of thyroid tumor cells. Additional preclinical studies
were conducted with met-F-AEA. Using the xenograft model
with KiMol cells it was determined that met-F-AEA prevented
thyroid tumor growth and this that effect was reversed by
antagonism of the CB1 receptor (Bifulco et al., 2001). Other
studies with KiMol cells confirmed the anti-tumor activity
of met-F-AEA and also indicated that this agent regulated
tumor angiogenesis (Portella et al., 2003). Specifically, tumors
isolated from met-F-AEA treated animals contained reduced
levels of VEGF and VEGF receptor compared to vehicle
treated animals. Furthermore, the reduction in VEGF signaling
could be prevented by blockade of CB1 receptor activity. In
another study, the synthetic cannabinoid, JWH-133, was tested
in the highly aggressive ARO cell tumor model (Shi et al.,
2008). Xenograft tumor growth using ARO/CB2 cells (a CB2
receptor overexpressing thyroid cancer cell line) was inhibited
in mice treated with JWH-133 compared to vehicle. Cell culture
experimentation suggested that JWH-133 toxicity was mediated
by the CB2 receptor in contrast to met-F-AEA which was
reported to initiate thyroid carcinoma cell death via CB1 (Portella
et al., 2003). The data collected thus far suggest that synthetic
EC system modulators represent novel therapeutic targets for
thyroid cancer. However, because of the scarcity of in vivo thyroid
cancer studies with cannabinoids, more extensive evaluation
is needed to confidently define the role of the ECS in this
malignancy.
SKIN CANCER
The epidermis is comprised of different cell types including
keratinocytes and melanocytes, which are the source of non-
melanoma skin cancer (NMSC) and melanoma, respectively.
Skin cancer is the most common cancer in the United States
with approximately 5.4 million new lesions (3.3 million cases) of
NMSC and more than 76,000 new cases of melanoma diagnosed
each year (American Cancer Society, 2016; Siegel et al., 2016).
Melanoma is more deadly and aggressive than NMSC. It is
estimated that over 10,000 patients will die from melanoma in
2016 (Siegel et al., 2016). Several in vitro and in vivo studies
suggest that the ECS plays a vital role in melanoma and
NMSC development and progression (reviewed in Soliman et al.,
2016a). It has been reported that CB1 and CB2 receptors were
expressed in human melanoma cell lines as well as in human
cutaneous melanoma biopsies (Blázquez et al., 2006). In addition,
circulating levels of the endocannabinoid, 2-AG, increased in
metastatic B16F10 mouse melanoma as well as in patients with
metastatic melanoma suggesting a link between the ECS and
melanoma progression (Sailler et al., 2014). Furthermore, in
human and murine normal keratinocytes and non-melanoma
skin tumors (e.g., papilloma, basal cell carcinoma, squamous cell
carcinoma) CB1 and CB2 receptors were expressed and were
required for the development of NMSC in vivo (Casanova et al.,
2003; Zheng et al., 2008).
Melanoma
The anti-tumor activity of phyto- and synthetic-cannabinoids
against melanoma was reported in different in vivo studies
using xenograft tumor models. Phytocannabinoid, 19-THC
decreased proliferation, increased death and reduced the growth
of CHL-1 melanoma xenografts (Armstrong et al., 2015). Using
CB1/CB2-receptor deficient mice (CB1/2−/−), Glodde’s group
demonstrated that the anti-tumor effect of19-THC onHCmel12
xenografts was dependent on cannabinoid receptors (Glodde
et al., 2015). Synthetic cannabinoids, with different affinities for
CB1 and CB2 receptors, have helped to shed light on the potential
of targeting CB1 and CB2 receptors in melanoma. Mixed
CB1/CB2 agonist, WIN-55212,2 decreased the progression and
metastasis of B16F10 melanoma cells in mice after subcutaneous
and intra-plantar implantation, respectively (Naeem et al.,
2006). Because the psychotropic effects of WIN-55212,2 are
primarily mediated by the CB1 receptor, the anti-tumor effects
of the non-psychoactive, CB2 selective cannabinoid, JWH-133
was examined. JWH-133 was as effective as WIN55212,2 in
inhibiting melanoma tumor growth, suggesting that the anti-
tumor activity of cannabinoids was mediated by CB2 receptor
activation (Naeem et al., 2006). Hence, the data generated thus far
indicate that cannabinoid receptor agonists may be appropriate
therapeutic targets for melanoma. Newer clinical approaches
to combat melanoma involve mobilization of cytotoxic T-cells
with monoclonal antibodies such as ipilimumab and nivolumab.
Since cannabinoids are known immunomodulators, the effects of
cannabinoids on cancer immunosurvailence must be addressed
in future studies to have a complete understanding of the
therapeutic potential of these molecules.
Non-melanoma Skin Cancer
Several studies report that cannabinoids and endocannabinoids
have anti-cancer activity against NMSC via cannabinoid receptor
dependent or independent pathways (Van Dross et al., 2013;
Soliman and Van Dross, 2015; Soliman et al., 2016b). There
are two well-known animal models for NMSC, the UVB-
light-induced skin carcinogenesis model (Fischer et al., 2007)
or the two-stage chemical carcinogenesis protocol using a
tumor initiator such as dimethylbenz[a]-anthracene (DMBA)
and a tumor promoter such as 12-O-tetradecanoylphorbol-
13-acetate (TPA) (Kiraly et al., 2016). Using CB1 and CB2
receptor deficient (CB1/2−/−) and wild type (CB1/2+/+) mice,
it was determined that CB1 and CB2 receptors were required
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for papilloma formation initiated by UVB-light. In contrast,
similar studies with CB1/2+/+ and CB1/2−/− mice in the
DMBA/TPA model demonstrated that cannabinoid receptors
were not required for skin tumorigenesis. Data from these two
different studies indicate that the involvement of ECS in skin
cancer development is dependent on the type of the stimulus
(Zheng et al., 2008; Gegotek et al., 2016). The in vivo anti-
tumor activities of different synthetic cannabinoids have also
been reported.WIN-55,212–2 and JWH-133 reduced the growth,
impaired vascularization, and reduced the expression of various
pro-angiogenic factors in the murine epidermal tumor cell
PDV.C57 xenograft model (Casanova et al., 2003). In a different
study, the anti-tumor activity of other synthetic cannabinoids was
analyzed in the DMBA/TPA skin carcinogenesis model where
JWH-018, JWH-122, and JWH-210 reduced tumor incidence
and multiplicity compared to vehicle treated animals (Nakajima
et al., 2013). Collectively, it appears that the ECS is involved
in the formation of UVB-induced NMSC and that phyto- and
synthetic- cannabinoids are capable of decreasing NMSC growth
in different tumor models. It will be important for future
investigations to include human NMSC tissue models (such as
PDX) in the examination of cannabinoid activity since many of
the existing reports primarily utilize mouse tissue xenograft and
carcinogen-induced cancer models.
ANTI-CANCER EFFECTS OF
CANNABINOIDS IN HUMANS
Human studies that investigate the pharmacotherapeutic benefits
associated with the use of cannabinoid ligands focus on
reductions in pain, spasticity and cognitive deficits in a number
of central and peripheral nervous system disorders (Velasco et al.,
2016). To date only a few cannabis-based pharmacological agents
are licensed for clinical use. In Europe, Sativex R© is approved for
treatment of spasticity associated with multiple sclerosis and in
Canada it is additionally approved as an adjunct analgesic for
cancer pain. The CB1 antagonist rimonabant (Acomplia R©) was
licensed for use in Europe to treat obesity and related conditions
but was discontinued due to adverse effects (Fijal and Filip, 2016).
In the United States and Europe, nabilone (Cesamet R©) and
dronabinol (Marinol R©) are approved compounds for prevention
of chemotherapy-induced nausea and vomiting. The emergence
of preclinical studies that demonstrate the anti-tumor effects of
cannabinoids are growing in number and have formed the basis
of limited clinical studies which are beginning to shed light on
the translational value of the preclinical work.
Guzman and colleagues were the first group to report a Phase
I human study of the anti-metastasic effects of 19-THC. In this
open-labeled two-part clinical trial, nine patients with recurrent
glioblastoma who were refractory to surgery and radiotherapy
were treated with intracranial 19-THC in combination with
high-dose chemotherapeutic agent, temozolomide (Temodar R©).
Following a washout phase (a period in a clinical trial where
patients receive no active medication), the safety and tolerability
of 19-THC was then compared to placebo (Clinical trial
ID# NCT01812603). The primary outcome measured was the
incidence of adverse effects in patients receiving the combination
of 19-THC and Temodar R©. Secondary measures were the
progression free survival at 6 months and overall survival.
Additional study outcomes have not yet been reported. 19-
THC was found to reduce tumor cell growth in vitro from 2
study participants and reduce tumor cell immunostaining in
these same patients. Importantly, intracranial administration
of 19-THC was found to be a safe and tolerable approach
with no apparent psychoactive effects (Gúzman et al., 2006).
In a 2011 case report by Foroughi et al. two children with
septum pellucidum/forniceal policytic astrocytomas experienced
tumor regression following craniotomies and partial excision.
The tumor regression occurred during the time that cannabis
was inhaled by the patients (Foroughi et al., 2011). In another
study, a 14-year-old female Philadelphia chromosome positive
patient who had been unsuccessfully treated with “traditional”
therapy (i.e., chemotherapy, bone marrow transplant and
radiation) for acute lymphoblastic leukemia experienced a
dose-dependent management of the condition with orally
administered cannabinoid extracts (Singh and Bali, 2013). A
clear limitation of the current human studies evaluating the anti-
cancer effects of cannabinoid compounds is the small patient
size. To date, no study findings have been replicated in multiple
cohorts. Moreover, the measured outcomes and study designs
are often variable across trials, making it difficult to compare
their findings. However, despite these challenges, the evidence
generated in these human studies are still informative and, when
taken together with the strong in vivo animal data demonstrating
anti-tumor effects of cannabinoids, offer promise for a clinical
role for cannabinoids in the eradication of tumors.
CONCLUSION
To gain an understanding regarding the translational and
therapeutic potential of cannabinoids, this review focused on
examining the overall efficacy of these molecules in animal
and human studies. The majority of in vivo animal studies
discussed here indicate that cannabinoids from plant, synthetic
and endogenous origin are capable of effectively decreasing
tumor growth and invasion (Table 1). Furthermore, clinical
studies evaluating cannabinoid efficacy in human subjects are
limited, yet these studies showed that cannabinoids may be safe
and effective anti-neoplastics. Because large scale clinical trials
are lacking, examining the activity of cannabinoids in clinically
translatable animal models (such as PDX) should be the goal of
future research as this approach may provide a more accurate
assessment of the therapeutic potential of cannabinoids.
This review also sought to couple in vivo animal studies with
in vitro experiments in order to examine proposed cannabinoid
mechanisms of action and to identify specific cellular targets. The
studies reviewed herein indicate that cannabinoids elicit activity
through cannabinoid receptor dependent and independent
pathways. Moreover, processes such as ceramide production,
ER-stress, autophagy, angiogenesis and matrix remodeling also
appear to regulate the anti-tumor activity of cannabinoids.
Hence, these investigations shed light on the role of cannabinoids
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on tumor growth in vivo and may ultimately pave the way for
the development of novel cannabinoid therapeutics for cancer
treatment.
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